Barinthus Biotherapeutics Statistics
Share Statistics
Barinthus Biotherapeutics has 39.54M shares outstanding. The number of shares has increased by 2.33% in one year.
| Shares Outstanding | 39.54M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.91% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 36.57M |
| Failed to Deliver (FTD) Shares | 520 |
| FTD / Avg. Volume | 1% |
Short Selling Information
The latest short interest is 5.32K, so 0.01% of the outstanding shares have been sold short.
| Short Interest | 5.32K |
| Short % of Shares Out | 0.01% |
| Short % of Float | 0.01% |
| Short Ratio (days to cover) | 0.07 |
Valuation Ratios
The PE ratio is -1.93 and the forward PE ratio is -0.78.
| PE Ratio | -1.93 |
| Forward PE | -0.78 |
| PS Ratio | 176.62 |
| Forward PS | 55.1 |
| PB Ratio | 0.76 |
| P/FCF Ratio | -2.51 |
| PEG Ratio | n/a |
Enterprise Valuation
Barinthus Biotherapeutics has an Enterprise Value (EV) of 12.53M.
| EV / Earnings | -0.17 |
| EV / Sales | 15.63 |
| EV / EBITDA | -0.18 |
| EV / EBIT | -0.15 |
| EV / FCF | -0.22 |
Financial Position
The company has a current ratio of 12.45, with a Debt / Equity ratio of 0.
| Current Ratio | 12.45 |
| Quick Ratio | 12.45 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -2996.93 |
Financial Efficiency
Return on equity (ROE) is -0.39% and return on capital (ROIC) is -40.22%.
| Return on Equity (ROE) | -0.39% |
| Return on Assets (ROA) | -0.34% |
| Return on Capital (ROIC) | -40.22% |
| Revenue Per Employee | 6.17K |
| Profits Per Employee | -564.21K |
| Employee Count | 130 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -3.17M |
| Effective Tax Rate | 0.04 |
Stock Price Statistics
The stock price has increased by -69.35% in the last 52 weeks. The beta is -0.58, so Barinthus Biotherapeutics's price volatility has been lower than the market average.
| Beta | -0.58 |
| 52-Week Price Change | -69.35% |
| 50-Day Moving Average | 1.1 |
| 200-Day Moving Average | 1.57 |
| Relative Strength Index (RSI) | 41.14 |
| Average Volume (20 Days) | 51.93K |
Income Statement
In the last 12 months, Barinthus Biotherapeutics had revenue of 802.00K and earned -73.35M in profits. Earnings per share was -1.91.
| Revenue | 802.00K |
| Gross Profit | 802.00K |
| Operating Income | -83.91M |
| Net Income | -73.35M |
| EBITDA | -71.06M |
| EBIT | -83.91M |
| Earnings Per Share (EPS) | -1.91 |
Balance Sheet
The company has 142.09M in cash and 12.98M in debt, giving a net cash position of 129.11M.
| Cash & Cash Equivalents | 142.09M |
| Total Debt | 12.98M |
| Net Cash | 129.11M |
| Retained Earnings | -176.59M |
| Total Assets | 188.69M |
| Working Capital | 119.58M |
Cash Flow
In the last 12 months, operating cash flow was -50.92M and capital expenditures -5.41M, giving a free cash flow of -56.34M.
| Operating Cash Flow | -50.92M |
| Capital Expenditures | -5.41M |
| Free Cash Flow | -56.34M |
| FCF Per Share | -1.47 |
Margins
Gross margin is 100%, with operating and profit margins of -10.46K% and -9.15K%.
| Gross Margin | 100% |
| Operating Margin | -10.46K% |
| Pretax Margin | -9.54K% |
| Profit Margin | -9.15K% |
| EBITDA Margin | -8.86K% |
| EBIT Margin | -10.46K% |
| FCF Margin | -7.02K% |
Dividends & Yields
BRNS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -185.44% |
| FCF Yield | -138.34% |
Analyst Forecast
The average price target for BRNS is $3, which is 191.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $3 |
| Price Target Difference | 191.3% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Scores
| Altman Z-Score | -0.86 |
| Piotroski F-Score | 3 |